Bliss GVS Pharma Limited's Board of Directors has approved a significant leadership transition, appointing the company's current Chief Executive Officer, S.N. Kamath, as Managing Director for a three-year term. The decision was made during a board meeting held on December 23, 2025, through video conferencing at the company's registered office.

Board Approval and Appointment Details

The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, has appointed Mr. S.N. Kamath (DIN: 00140593) as Managing Director for three consecutive years. The appointment is effective from the date of passing the Special Resolution, subject to shareholder approval through postal ballot.

Leadership Profile and Background

Mr. S.N. Kamath brings extensive experience in the pharmaceutical sector to his expanded role. A seasoned professional from Mulki, Karnataka, he began his career in Mumbai before entering the pharmaceutical industry through exports of anti-malarial drugs under GVS Labs. He subsequently acquired Bliss Chemicals Pharmaceuticals, leading to the formation of Bliss GVS Pharma Limited, where he serves as promoter.

Under his leadership, the company has achieved significant milestones:

• Expanded presence to over 60 countries
• Established multiple state-of-the-art manufacturing units
• Received the Pharmexcil Outstanding Export Performance Award (2008-09)
• Maintained close association with company operations and strategic growth

Family Connections and Governance

The appointment involves family relationships within the company's leadership structure. Mr. S.N. Kamath is the father of Dr. Vibha Gagan Sharma and Mrs. Shruti Vishal Rao, both serving as Whole-Time Directors of the company. The disclosure confirms that Mr. Kamath is not debarred from holding the office of Director by virtue of any SEBI order or other regulatory authority.

Meeting Details and Regulatory Compliance

The Board of Directors meeting commenced at 11:47 A.M. and concluded at 13:45 P.M. on December 23, 2025. The board also approved the draft of the Postal Ballot Notice for seeking member approval for Mr. Kamath's appointment as Managing Director. The postal ballot process will enable shareholders to vote on this leadership transition, following regulatory requirements under SEBI guidelines.

The appointment represents a consolidation of leadership roles, combining the Managing Director and Chief Executive Officer positions under Mr. Kamath's stewardship, pending shareholder approval.

Bliss GVS Pharma Limited , a prominent player in the pharmaceutical sector, has taken a significant step to enhance employee engagement and align their interests with the company's growth. The company's ESOP Allotment Committee has approved the issuance of 66,380 new equity shares under its Employee Stock Option Plan (ESOP) 2019.

Key Details of the ESOP Allotment

This strategic move by Bliss GVS Pharma demonstrates its commitment to fostering a sense of ownership among its employees and aligning their interests with the company's long-term success.

Impact on Share Capital

The allotment has resulted in a marginal increase in the company's total issued share capital. Prior to this allotment, the company had 10,57,22,592 equity shares. The addition of 66,380 new shares represents an increase of approximately 0.63% in the total number of outstanding shares.

Financial Context

While the ESOP allotment itself doesn't directly impact the company's financial performance, it's worth noting some key financial metrics to provide context:

These figures indicate that Bliss GVS Pharma has been experiencing steady growth in its asset base and shareholder equity.

Conclusion

The recent ESOP allotment by Bliss GVS Pharma underscores the company's focus on employee retention and motivation. By offering equity ownership to eligible employees, the company aims to create a stronger sense of belonging and commitment among its workforce. This move aligns with modern corporate practices that emphasize the importance of employee engagement in driving long-term organizational success.

As the newly allotted shares come with a 6-month lock-in period, it ensures that the participating employees have a vested interest in the company's performance over the coming months. This alignment of interests between the employees and the company could potentially contribute to improved productivity and overall corporate performance.